Frontlight ResearchEarly access
CompletedPhase 2/3
Intranasal Insulin to Prevent Intensive Care Unit Delirium
Key facts
- Who runs it
- Radboud University Medical Center
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 30 people enrolled
- Started
- 30 Apr 2026
- Ended
- 30 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Intranasal insulin-40U
- Intranasal sodium chloride 0.9%
- Record updated
- 3 August 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥65 years
- Planned surgical admission to the ICU of the Radboudumc following complex cardiac surgery with CPB. Complex cardiac surgery is defined as all cardiac on-pump procedures except for isolated CABG
- Able to receive intranasal spray (no obstructive nasal pathology precluding administration)
- Informed consent from patient
Who cannot take part
- Contra-indication for nasal administration (severe nasal pathology, recent nasal/sinus surgery, active epistaxis, active rhinitis, obstruction of either one or both nostrils)
- Participating in other investigational medication trial
- Non-complex or off-pump cardiac surgery
- Known allergy/hypersensitivity to insulin or formulation excipients
- Delirium at hospital admission
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to assess the feasibility, tolerability, and exploratory efficacy of intranasal insulin to prevent delirium in ICU patients aged ≥65 years after complex elective cardiac surgery with cardiopulmonary bypass
The 2 groups in the trial
- Intranasal insulinTreatment being tested
Intranasal insulin administered twice daily. Each administration consists of two sprays of 10 IU (0.1 ml) in alternating nostrils, totalling to 40 IU per day.
Treatment: Intranasal insulin-40U
- Intranasal placebo (NaCl 0.9%)Placebo, for comparison
Intranasal placebo (sodium chloride 0.9%) administered twice daily. Each administration consists of two sprays of 0.1 ml in alternating nostrils, totalling to 0.4 mL per day.
Treatment: Intranasal sodium chloride 0.9%
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Intranasal Insulin for the Prevention of Delirium in ICU Patients Undergoing Elective Cardiac Surgery: a Randomized, Double-blind, Placebo-controlled Pilot Trial (INSPIRE)
- Record updated
- 3 August 2026